Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren P Mason

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Neuro-Oncology Practice|January 20, 2023
Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastomaAngela Sekely, Lori J Bernstein, Kristin L Campbell, et al.
Neuro-Oncology|October 11, 2017
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglioMartha Nowosielski, Benjamin M Ellingson, Olivier L Chinot, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
Canadian Expert Consensus Recommendations for the Diagnosis and Management of Glioblastoma: Results of a Delphi StudyWarren P Mason, Rebecca A Harrison, Sarah Lapointe, et al.
Genome Biology|January 28, 2015
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastomaSebastian Kurscheid, Pierre Bady, Davide Sciuscio, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 12, 2025
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedureJonas Willmann, Joost J C Verhoeff, Orit Kaidar-Person, et al.
Neuro-Oncology|June 14, 2018
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placeboBenjamin M Ellingson, Lauren E Abrey, Josep Garcia, et al.
Neuro-Oncology|September 2, 2016
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trialsBenjamin M Ellingson, Robert J Harris, Davis C Woodworth, et al.
Neuro-Oncology Advances|November 12, 2021
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trialAndrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Neuro-Oncology Advances|January 31, 2022
Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trialAndrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumorsIan Krop, Tim Demuth, Tina Guthrie, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Neuro-Oncology Practice|January 20, 2023
Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastomaAngela Sekely, Lori J Bernstein, Kristin L Campbell, et al.
Neuro-Oncology|October 11, 2017
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglioMartha Nowosielski, Benjamin M Ellingson, Olivier L Chinot, et al.
Current Oncology (Toronto, Ont.)|April 25, 2025
Canadian Expert Consensus Recommendations for the Diagnosis and Management of Glioblastoma: Results of a Delphi StudyWarren P Mason, Rebecca A Harrison, Sarah Lapointe, et al.
Genome Biology|January 28, 2015
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastomaSebastian Kurscheid, Pierre Bady, Davide Sciuscio, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 12, 2025
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedureJonas Willmann, Joost J C Verhoeff, Orit Kaidar-Person, et al.
Neuro-Oncology|June 14, 2018
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placeboBenjamin M Ellingson, Lauren E Abrey, Josep Garcia, et al.
Neuro-Oncology|September 2, 2016
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trialsBenjamin M Ellingson, Robert J Harris, Davis C Woodworth, et al.
Neuro-Oncology Advances|November 12, 2021
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trialAndrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Neuro-Oncology Advances|January 31, 2022
Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trialAndrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumorsIan Krop, Tim Demuth, Tina Guthrie, et al.
Pageof 12